NCLAT: Can File Appeal against NCLT Order Initiating Insolvency Process against Personal Guarantors  ||  NCLAT: Assets Reflecting in Corporate Debtor’s Balance Sheet form Part of Liquidation Estate  ||  NCLAT: Adjudicating Authority Must Conduct Independent Assessment under IBC  ||  NCLAT: Can’t Preclude Financial Creditors from Filing Applic. in Case of Settlement Agreement Breach  ||  NCLT: Can’t Call Speculative Investment a 'Financial Debt' in Absence of Commercial Effect of Borrowi  ||  NCLAT: Committee of Creditors Within its Right to Resolve to Liquidate Go Airlines  ||  AP HC: Revealed Particulars of Invest. Not Adequately Substantiated Can Damage Reputation of Persons  ||  J&K HC: Administrative Officers Can’t Claim Seniority on Basis of Unfilled Vacancies  ||  Bombay High Court: One Needs to be Mindful of the Object Behind the Consumer Protection Act  ||  J&K HC: Can’t Put Accused under Prev. Detention Only because His Release Affects Public Confidence    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved